Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller may cut side effects after hip surgery

NCT ID NCT01536301

Symptom relief Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a pain medicine called oxycodone causes fewer side effects than morphine after hip replacement surgery. About 246 adults took part. The goal was to see if oxycodone reduces problems like nausea, vomiting, itching, and breathing trouble by half. The results help doctors choose safer pain relief for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

246 people

The number who actually took part.

Start date

Jun 2012

Finished

Nov 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for a 4 month follow-up * The patient weight between 50 and 100 kg * Patient scheduled for unilateral hip arthroplasty * Patient has creatinine clearance \> 50 ml/min (Cockroft) * Patient with ASA-PS score of 1, 2 or 3 (American Society Anesthesiology - Physical Status) Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * Patient with ASA score of 4 * Patient has a known deficit in cytochrome P450 * Uncontrolled epilepsy * Chronic alcoholism * Patient already taking opiate agonist on a long term basis (codeine, dextromoramide, dihydrocodeine, oxycodone po, morphine-like antitussif) * Patient already taking agonist-antagonists on a long term basis (buprenorphine, nalbuphine, pentazocine) * The patient is under treatment for liver inducing enzyme cytochrome P450: anti-infectives (e.g. rifampicin, rifabutin, nevirapine, griseofulvin), antiepileptic (phenobarbital, phenytoin) * the patient has an allergy to opiates * the patient has chronic renal insufficiency: creatinine clearance \< 50 ml / min (Cockroft formula) * the patient has severe hepatic insufficiency(transaminase and/or alkaline phosphatase x 3/nal)) * patient with porphyria, intracranial hypertension, a syndrome subocclusive or ileus

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthroplasty, replacement, hip are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthroplasty, replacement, hip

Contacts and locations

Locations

  • APHP - Groupe Hospitalier Pitié-Salpetrière

    Paris, 75013, France

  • CHU de Nîmes - Hôpital Universitaire Carémeau

    Nîmes, Gard, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.